Common Stock, Par Value $0.001 Per Share
- Symbol
- ECOR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
electroCore, Inc.
ECORNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, electroCore, Inc. (the “Company”) issued a press release (i) announcing its financial results for the third quarter ended September 30, 2026, and (ii) providing guidance for the full year of 2026 and certain periods of 2027. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference.…
Press release in this filing
electroCore Announces Third Quarter 2026 Financial Results →Company context
electroCore, Inc. and its subsidiaries are a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. For more information, visit www.electrocore.com.
Current securities
Recent company filings
- 10-Q filingNov 4, 2026
- 4 filingSep 10, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders · Regulation FD DisclosureSep 9, 2026
- 10-Q filingAug 6, 2026
- Results of Operations and Financial ConditionAug 6, 2026
Registered securities in this filing
electroCore, Inc · 8-K · Filed 2026-11-04
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item
2.02 Results of Operations and Financial Condition.
On
November 4, 2026, electroCore, Inc. (the “Company”) issued a press release (i) announcing its financial results for the third
quarter ended September 30, 2026, and (ii) providing guidance for the full year of 2026 and certain periods of 2027. A copy of the press
release is furnished herewith as Exhibit 99.1 and incorporated by reference.
The
information contained in this Item 2.02 and Item 9.01 in this Current Report on Form 8-K, including the accompanying Exhibit 99.1 hereto,
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings,
unless expressly incorporated by specific reference in such filing.
Filed exhibits (1)
Exhibit 99.1 electroCore Announces Third Quarter 2026 Financial Results Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million in the third quarter of 2025 Net loss of $1.3 million decreased 61% from prior year with Adjusted EBITDA net loss improving 67% from prior-year period Company to host a conference call and webcast today, November 4, 2026, at 4:30 pm EST ROCKAWAY, NJ, November 4, 2026 (GLOBE NEWSWIRE) - electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced financial results for the third quarter ended September 30, 2026. The Company reported quarterly revenue of $9.7 million, an increase of approximately 12% year-over-year, driven by continued growth in U.S. prescription sales in the U.S. Department of Veterans Affairs (“VA”), with GAAP net loss improving by $2.0 million to $1.3 million or 61% from prior year and Adjusted EBITDA loss improving by nearly $1.4 million to $0.7 million or 67%, ahead of expectations. “This quarter reflects the early stages of a more efficient commercial organization,” said Joshua Lev, Co-Chief Executive Officer, President, and Chief Financial Office…
Open exhibit ↗